The MALDI Biotyper has obtained the IVD-CE mark in selected European countries, and Bruker is planning to submit the MALDI Biotyper to the US FDA for clearance.
The MALDI Biotyper is a MALDI-TOF mass spectrometry based platform for rapid molecular identification of bacteria, yeast and fungi and its carefully curated database includes quality-controlled entries of over 3,900 strains from 2,000 well-characterized microbial species.
The MALDI Biotyper offers considerably faster time-to-result (TTR), high specificity, very low false positive rates, low operational costs, and low technical barriers for new operators, the company said.
Bruker Daltonics Business Development executive director George Goedesky said they have enjoyed collaborating with Dynacare, and we are very pleased they have selected the MALDI Biotyper for use both in their research and their routine microbial identification production facility.
"We look forward to continuing to work with Dynacare on further applications of the MALDI Biotyper microbiology platform," Goedesky said.
